Dr Reddy's gets USFDA nod to launch new ovarian cancer drug in US

Alza Corporation's Doxil injection had sales of $196 mn in the 12 months ended March 2017

Hyderabad-based Dr Reddy's Laboratories has received approval from US Food and Drug Administration (US FDA) to launch Doxorubicin Hydrochloride Liposome injection in the US market. 

This product is the therapeutic equivalent generic version of Doxil, a chemotherapy drug which is used in the treatment of certain types of cancer such as ovarian cancer, AIDS-related Kaposi's sarcoma and multiple myeloma. It is meant for intravenous use in slowing or stopping cancer cell growth. The US FDA approval was an outcome of extensive collaboration with the company's partner Natco Pharma Limited, on R&D and manufacturing capabilities, according to Dr Reddy's. 

"This approval represents the